Close
Close

Spinal Muscular Atrophy (SMA) is the leading genetic cause of death in infants and toddlers and is associated with a high rate of childhood mortality in its most severe forms. In a collaboration between Roche Pharma Research and Early Development (pRED), PTC Pharmaceuticals and the SMA Foundation, orally available molecules were discovered that may specifically correct a certain genetic defect in this devastating disorder. In mouse models of SMA, the compounds allow the animals to survive, grow and develop a normal neuromuscular system. We are working together to make a difference for SMA patients and their families.
For more information: www.roche.com

Learn more about:

Access Programs

by Abidemi Uruejoma
88 views 1 month ago
by Abidemi Uruejoma
96 views 2 months ago
by Abidemi Uruejoma
91 views 2 months ago
2.11111111111
2.1 from 9 votes
Free Newsletter
Find a Clinical Trial
Related Videos
by Abidemi Uruejoma
158 views
by Abidemi Uruejoma
1,216 views
by Abidemi Uruejoma
7,232 views
News Articles